ReZolve Bioresorbable Sirolimus-Eluting Coronary Scaffold: Pilot trial started

Reva began the open-label, international RESTORE pilot trial to evaluate the ReZolve Bioresorbable Sirolimus-Eluting Coronary Scaffold in 50 patients with symptomatic coronary artery disease due to on...